Financial informations

Since its inception, ErVimmune is financially supported by BPIFrance, Cancéropôle Lyon Auvergne-Rhône-Alpes and Agence Nationale de la Recherche.

End of 2020, a life science investor, Seventure (seed investment of 2.5 M€) joined the adventure!

Grants & awards

ErVimmune rewarded*

“CLARA’s support will enable us to rapidly strengthen the resources set up for our therapeutic project.

We hope to be able to bring a first vaccine candidate into the clinic within two years,”


*grant given to our academic lab on the therapeutic cancer vaccine project

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice


> Home

> About us

> Sciences

> Investors

> Join us

> Contact



+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go